Nov 2, 2023 · Conclusion. In TE NDMM pts, the addition of isatuximab to KRd induction and consolidation significantly increased MRD negativity rates in every treatment phase as …

Dec 9, 2024 · Gay F, Roeloffzen W, Dimopoulos MA, et al: Results of the phase III randomized Iskia trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs carfilzomib-lenalidomide …

Dec 21, 2023 · Francesca Gay, MD, PhD, presents results from the phase III randomized IsKia trial investigating isatuximab-carfilzomib-lenalidomide-dexamethasone as pre-transplant …

Jan 1, 2024 · Conclusion: Isa-KRd effectively induces high rates of sustainable MRD negativity in the difficult-to-treat HRNDMM population, regardless of transplant status, translating into a …

Dec 11, 2023 · Dr Gay presented these results from IsKia (ClinicalTrials.gov Identifier: NCT04483739) during the plenary session at the ASH Annual Meeting 2023. The trial enrolled …

Abstract #4 | Presentation at the 65th ASH Annual Meeting and Exposition | December 9‒12, 2023

“The increase in MRD negativity rate in the Isa-KRd arm was seen in all the subgroups of patients analyzed at the 10 −5 and 10 −6 cutoffs. Interestingly, this was true for standard-risk, high-risk, …

Gay F, Roeloffzen W, Dimopoulos MA, et al. Results of the phase III randomized IsKia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide …

The MRD negativity advantage, both at 10 -5 and 10 -6, was retained in all subgroups analyzed (Figure), with similar benefit in pts with standard-risk (SR) and HiR features.

Jun 4, 2024 · Isa-VRd significantly increased MRD endpoints, including the 18-month negativity rate at 10 -5, the primary endpoint, compared with IsaRd. This study proposes Isa-VRd as a …